11th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals | Lisbon
David Favre, VP Translational Medicine, will present at the EIP Symposium in Lisbon, which will be held February 17-19, 2020.
AAV Immunogenicity: Novel Vectors & New Questions
Tuesday, Feb. 18
Cell and gene therapies are rapidly developing as novel therapeutic options for patients with unmet medical needs. These encompass rare genetic diseases, including primary immune deficiencies (e.g. ADA-SCID), metabolic diseases (e.g. retinopathies, hemophilia, lysosomal storage diseases), muscular dystrophies (e.g. DMD, SMA), hemoglobinopathy (e.g. b-thalassemia) and neurodegenerative disorders (e.g. Alzheimer’s, Parkinson’s, Huntington’s diseases). It now extends to non-monogenic disease areas, such as chronic inflammatory diseases (e.g. arthritis), cardio-vascular diseases (e.g. congestive heart failure) and refractory/relapsed cancers (e.g. TCR/CAR-T cell therapies).
AAVs hold a unique position as one of the most effective and safe vectors for direct in vivo gene delivery of therapeutic genes. The biology, pharmacology and immunogenicity of AAV gene delivery in vivo are essential for success. As AAV vectors progress along with new strategies to dose or re-dose subjects with pre-existing immunity, new questions will arise on the safety and immunogenicity of novel vectors. AskBio will discuss the opportunities and challenges of novel AAVs from an immunogenicity standpoint.